Novavax Prepared to Deliver Protein-based Monovalent XBB COV

Novavax has developed a protein-based monovalent XBB.1.5 COVID vaccine candidate and is manufacturing at commercial scale with the intent to be in market during the fall vaccination campaignNovavax... | June 15, 2023

Related Keywords

, Erika Schultz , Johnc Jacobs , Ali Chartan , Exchange Commission , Linkedin , World Health Organization , Vaccine Administration Errors , Prnewswire Novavax Inc , Novavax Inc , Drug Administration , Nasdaq , Products Advisory Committee , Vaccination Program , European Medicines Agency , Related Biological Products Advisory Committee , Chief Executive Officer , Emergency Use Authorization , Coronavirus Disease , Acute Allergic Reactions , Vaccine Effectiveness , Adverse Events , Vaccine Administration , Vaccine Adverse Event Reporting System , Multisystem Inflammatory Syndrome , Fax Number , Telephone Number , Financial Condition , Annual Report , Quarterly Reports , Novavax , Nc Stock Exchange , News , Information , Press Release , Gas , Eveloped , Monovalent , Covid , Vaccine , Candidate , End , Us , Manufacturing , It , Commercial , Scale , Ith , The , Intent , O , He , N , Market , During , Wall , Accination Nvax Us6700024010 ,